The current status and future directions of myxoma virus, a master in immune evasion

Bart Spiesschaert, Douglas McFadden, Katleen Hermans, Hans Nauwynck, Gerlinde R. Van De Walle

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of MYXV in rabbits as well as its potential in human medicine in the twenty-first century.

Original languageEnglish (US)
Article number76
JournalVeterinary Research
Volume42
Issue number1
DOIs
StatePublished - Aug 29 2011
Externally publishedYes

Fingerprint

Myxoma virus
immune evasion
Immune Evasion
Rabbits
rabbits
medicine
Arthropod Vectors
Medicine
myxomatosis
Sylvilagus
Viruses
immunomodulators
viruses
Oryctolagus cuniculus
Direction compound
Immunologic Factors
skin lesions
Population
cardiovascular diseases
arthropods

ASJC Scopus subject areas

  • veterinary(all)

Cite this

The current status and future directions of myxoma virus, a master in immune evasion. / Spiesschaert, Bart; McFadden, Douglas; Hermans, Katleen; Nauwynck, Hans; Van De Walle, Gerlinde R.

In: Veterinary Research, Vol. 42, No. 1, 76, 29.08.2011.

Research output: Contribution to journalReview article

Spiesschaert, Bart ; McFadden, Douglas ; Hermans, Katleen ; Nauwynck, Hans ; Van De Walle, Gerlinde R. / The current status and future directions of myxoma virus, a master in immune evasion. In: Veterinary Research. 2011 ; Vol. 42, No. 1.
@article{797632edd4d64248879b12d9e8a1943b,
title = "The current status and future directions of myxoma virus, a master in immune evasion",
abstract = "Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of MYXV in rabbits as well as its potential in human medicine in the twenty-first century.",
author = "Bart Spiesschaert and Douglas McFadden and Katleen Hermans and Hans Nauwynck and {Van De Walle}, {Gerlinde R.}",
year = "2011",
month = "8",
day = "29",
doi = "10.1186/1297-9716-42-76",
language = "English (US)",
volume = "42",
journal = "Annales de Recherches Veterinaires",
issn = "0928-4249",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The current status and future directions of myxoma virus, a master in immune evasion

AU - Spiesschaert, Bart

AU - McFadden, Douglas

AU - Hermans, Katleen

AU - Nauwynck, Hans

AU - Van De Walle, Gerlinde R.

PY - 2011/8/29

Y1 - 2011/8/29

N2 - Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of MYXV in rabbits as well as its potential in human medicine in the twenty-first century.

AB - Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of MYXV in rabbits as well as its potential in human medicine in the twenty-first century.

UR - http://www.scopus.com/inward/record.url?scp=80051988043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051988043&partnerID=8YFLogxK

U2 - 10.1186/1297-9716-42-76

DO - 10.1186/1297-9716-42-76

M3 - Review article

VL - 42

JO - Annales de Recherches Veterinaires

JF - Annales de Recherches Veterinaires

SN - 0928-4249

IS - 1

M1 - 76

ER -